NP137
Solid Tumors (e.g., Endometrial, Pancreatic Cancer)
Phase 2Active
Key Facts
Indication
Solid Tumors (e.g., Endometrial, Pancreatic Cancer)
Phase
Phase 2
Status
Active
Company
About NETRIS Pharma
NETRIS Pharma is a pioneering French biotech focused on overcoming cancer treatment resistance by targeting the novel Netrin-1 pathway. Its lead asset, NP137, is an anti-Netrin-1 monoclonal antibody with demonstrated safety and anti-tumoral activity in over 300 patients across several solid tumors. The company leverages a deep scientific foundation from its parent research centers and strategic partnerships with industry leaders like MSD to advance its pipeline in high unmet need cancers. Its integrated model within a top-tier cancer center provides a significant advantage in translational and clinical development.
View full company profile